JB Chemicals and Pharmaceuticals Ltd Q2FY24 Result Update

JB Chemicals and Pharmaceuticals Ltd. recently shared their financial results for the second quarter of the fiscal year 2024, and they’ve done pretty well. Their overall sales went up by 8.9% compared to last year, reaching Rs. 8,817 million, which was more than what experts had predicted.

A big part of their success came from their domestic sales of medicines (like drugs sold within India), which grew by 10.8%. This growth was mainly because they did well in selling long-term treatment drugs and some new brands they’ve acquired. However, sales of medicines for short-term illnesses weren’t as strong.

Their international sales also saw a good increase of 8.7% despite tough market conditions. Additionally, their business in contract drug manufacturing (where they make medicines for other companies) did well too, making Rs. 1,150 million, a 5% increase from last year.

Their profits before considering certain expenses (EBITDA) and their net income after all expenses (Profit after Tax) both saw significant increases from last year. This means they not only made more sales but also managed to keep more of that as profit.

Their chronic illness drug sales did really well, growing faster than the overall market for these types of drugs. Looking forward, the company expects to keep growing, especially with new drug launches, better sales efforts, and expanding their contract manufacturing business. They’re also planning to grow more internationally and focus on improving their productivity. Overall, JB Chemicals seems to be on a good path, expecting to continue its growth and make more money in the coming years.

JB Chemicals & Pharmaceuticals Ltd. recently had a good quarter in their domestic (Indian) market, mainly because of strong sales in their chronic illness medicines and some new brands they’ve acquired. They expect to keep doing better than the overall market by focusing on their big brands in areas like heart failure, children’s health, and cholesterol-lowering drugs. They’re also planning to launch new products.

In their chronic illness portfolio, they’re really outdoing the market. Their major brands are selling well, and they’re adding new versions to their existing products. For example, their drug Cilacar now has 10 different types, with one variant, Cilacar T, becoming particularly successful.

Azmarda, a heart failure medication, is another area where they’re doing well. Even though they reduced its price, they’re selling more of it, which is balancing things out. They expect this drug to grow significantly in the next 2-3 years.

Regarding their spending on new projects (capex), they spent Rs. 93 crores in the first half of the year, mainly to expand their lozenge manufacturing facility. They plan to spend a total of Rs. 145 crores for the year, which includes buying land and maintaining their facilities.

The company also focuses on making their medical representatives (MRs) more effective. They currently have over 2,200 MRs, and each is now bringing in more revenue than before. They want to increase this even further.

Their Contract Manufacturing Organization (CMO) business, which makes products for other companies, along with their domestic formulation business, made up 68% of their total sales this quarter. Their lozenge products are in high demand, and they’re planning to introduce more products and expand into new areas and therapies to grow their business in the future.